Small Molecule of Secreted Clusterin Promotes Mitochondrial Function, Synaptic Plasticity and Improved Memory in an Alzheimer's Disease Mouse Model
This study introduces a novel class of sCLU-enhancing compounds, highlighting a promising strategy to mitigate AD pathology. DDL-357 shows potential to address primary drivers of AD while supporting neuroprotective mechanisms and improving memory in AD models. These findings support further development of DDL-357, with future studies potentially including larger preclinical cohorts, expansion to rat models, and additional biomarker analysis.
Authors
- Chunni Zhu
- Jesus Campagna
- Gazmend Elezi (ORCID: https://orcid.org/0000-0003-4087-3431)
- Varghese John (ORCID: https://orcid.org/0000-0001-7675-2426)
- Barbara Jagodzinska (ORCID: https://orcid.org/0009-0006-5706-3725)
- Whitaker Cohn (ORCID: https://orcid.org/0000-0001-9198-8904)
- Julian P. Whitelegge (ORCID: https://orcid.org/0000-0003-2763-7733)
- Dongwook Wi
- Samar Padder
- Patricia Spilman
- Jessica Lee
- Sahiba Beniwal
Institutions
- University of California, Los Angeles (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_104473
- Primary Topic
- Clusterin in disease pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00